Friday, June 13, 2014

VistaGen Therapeutics, Inc. (VSTA) Stands to Reverse Tremendous Costs of Drug Failure with Pluripotent Stem Cell Technology

For 16 years, California-based VistaGen Therapeutics has worked with key collaborators to develop proprietary technologies which produce several types of several types of mature, functional adult human cells for drug rescue application. In its drug rescue model, the company leverages its two biological assay systems, CardioSafe 3D™ and LiverSafe 3D™, and modern medicinal chemistry to generate novel, safer variants of once-promising drug candidates that were terminated due to unexpected heart or liver safety issues.

In laymen’s terms, “drug rescue” refers to research and development efforts that use small molecule drug candidates that had been discovered and validated in medical efficacy tests, but were discontinued due to health safety concerns before they obtained FDA approval. Many of these drug candidates were shelved due to heart- or liver-related concerns.

When a pharmaceutical company develops a new drug candidate, the company often invests a decade-worth of dedicated efforts and millions of dollars in the drug candidate’s discovery, optimization, and validation of its medical potency. When a drug candidate is terminated, that equates to tens of millions of dollars and countless man-hours going down the drain.  Nearly one-third of all drug candidates fail in preclinical or clinical development due to unexpected health safety risks arising during the process.

From years of development, VistaGen Therapeutics has come up with a proprietary stem cell technology platform that it believes may be an answer. The company’s platform, Human Clinical Trials in a Test Tube™, enables drug candidates to be tested for toxicity concerns in their early stages of development, reducing the staggering costs and time invested when a drug candidate fails. Human Clinical Trials in a Test Tube™ consists of VistaGen’s CardioSafe 3D™ and LiverSafe 3D™ systems.

In 2013, the U.S. pharmaceutical industry spent more than $51 billion in drug research and development. With heart and liver safety issues as a Top reason for why many drug candidates are discontinued, VistaGen Therapeutics aims to recapture substantial value from the prior investment by pharmaceutical companies and others in failed drug candidates by reintroducing them to the biomedical space as new, proprietary variants of the original drug candidates.

For more information, visit: http://www.vistagen.com/

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net


No comments: